

DAFTAR PUSTAKA

1. Children's oncology group. Long-term follow-up care for pediatric cancer survivors. *Pediatrics*. 2009; 123:906-15
2. Dickerman JD. The late effect of childhood cancer therapy. *Pediatrics* 2007; 119:554-62
3. American speech-language-hearing association. Effect of hearing loss on development. Diunduh dari: <http://otologytextbook.com>. Diakses 15 Juli 2011
4. Fred Hutchinson cancer research center. Hearing loss. Diunduh dari <http://www.survivorshipguidelines.org/>. Diakses 15 Juli 2011.
5. Cancer center Guangzhou. Buku ajar onkologi klinis (terjemahan). Edisi ke-2. Balai Penerbit Fakultas Kedokteran Universitas Indonesia. Jakarta. 2008.h.634-57
6. Sukardja IDG. Neoplasia. Dalam: Sjamsuhidayat R dan Jong WD. Buku Ajar Ilmu Bedah. Edisi revisi. Penerbit buku kedokteran EGC. Jakarta. 1997.h.156-62
7. Gavane YN, Shete AS, Bhagat AK, Shinde VR, Bong KK, Khairnar GA dkk. Solid tumor: facts, challenges and solutions. *IJPSR*. 2011; 2(1):1-12
8. Sukardja IDG. Dasar-dasar kemoterapi kanker. Dalam Sukardja IDG, penyunting. *Onkologi klinik*. Edisi ke-2. Airlangga University Press. Jakarta. 2000.h.239-55
9. Schultz C, Gomez MVS, Liberman PHP dan Carvalho AL. Report on hearing loss in oncology. *Braz J Otolaryngol*. 2009; 75(5):634-41
10. Rybak LP dan Ramkumar V. Ototoxicity. *Kidney Int*. 2007; 72:931-35
11. Ekborn A. Cisplatin-induced ototoxicity, pharmacokinetics, prediction and prevention (Tesis). Stockholm 2003
12. Li Y, Womer RB dan Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. *Eur J Cancer*. 2004; 40(16):2445-51
13. Simon T, Hero B, Dupuis W, Selle B dan Berthold. The incidence of hearing impairment after successful treatment of neuroblastoma. *Klin Padiatr*. 2002; 214:149-152
14. Bertolini, Lassale, Mathilde, Mercier, Guilaine, et all. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. *Pediatr hematol oncol*. 2004; 26:649-55
15. Lakhai JM, Crul M, Zuur L, Baal P, Beimen JH, Simis YJ, dkk. Relationship between cisplatin administration and the development of ototoxicity. *J Clin Oncol*. 2006; 24:918-24
16. Wang LF, Kuo WR, Ho KY, Lee KW dan Lin CS. Hearing loss in patients with nasopharyngeal carcinoma after chemotherapy and radiation. *Kaoshiung J Med Sci*. 200; 19:163-9.
17. Fossa BAJ, Zarowski A, Milani F dan Orrechia R. Radiotherapy-induced ear ototoxicity. *Cancer Treat Rev*. 2003; 29:417-30.
18. Ross CJ, Katzov EH, Dube MP. Genetik variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. *Nat Genet*. 2009; 41:1345-9
19. Lendier W dan Tuttle CL. Monitoring and management of ototoxiciy. Dalam: Atman AJ, penyunting. *Supportive care of children with cancer: current therapy and guideline from the children's oncology group*. Edisi ke-3. London. The John Hopkins University Press. 2004.
20. Siddik ZH. Mechanisms of action of cancer chemotherapy agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. Dalam: Alison MR, penyunting. *The Cancer Handbook*. Edisi pertama. 2002.
21. Reedijk J. Increased understanding of platinum anticancer chemistry. *Pure Appl. Chem*. 2011; 83(9):1709-19
22. Cameron JH, Allen PJ. Cisplatin ototoxicity in children: implications for primary care providers: review literature. *Pediatr Nurs*. 2009; 35(2):121-27

23. Kasparkova J, Novakova O, Vrana O, Intini F, Natile G dan Brabec V. Molecular aspects of antitumor effects of a new platinum (IV) drug. *Mol. Pharmacol.* 2006; 70:1708-1719.
24. Truong MT, Winzelberg J, Chang KW. Recovery from cisplatin-induced ototoxicity: a case report and review. *Intl. J. Oto.* 2007; 71,1631-8
25. Husain K, Scott B, Whitworth C dan Rybak LP. Time response of carboplatine-induced hearing loss in rat. *J. Heares.* 2004; 191:110-118
26. Wright A, Forge A dan Kotecha B. Ototoxicity. Dalam: Kerr AG, penyunting. *ScottBrown's otolaryngology*. Edisi ke-6. Penerbit Butterworth Heinemann. London. 1987
27. American speech-language-hearing association. Audiologic management of individuals receiving cochleotoxic drug therapy. Diunduh dari www.asha.org/policy. Diakses tanggal 15 Juli 2012
28. Soetirto I, Hendarmin H, dan Bashiruddin J. Gangguan pendengaran (tuli). Dalam : Supardi EA, Iskandar N, Bashiruddin J, Restuti RD. *Buku ajar ilmu kesehatan telinga hidung tenggorok kepala dan leher*. Edisi ke-6. Jakarta. Balai penerbit FKUI, 2007. h. 10-22
29. Grewal S, Merchant T, Reymond R, McInerney, Hodge C dan Shearer P. Auditory late effects of childhood cancer therapy: a report from the children's oncology group. *Pediatrics.* 2010; 125(4):e938-50.
30. Lwanga dan Lameshaw. *Sample size determination in health studies: practical manual*. World Health Organization. Geneva. 1991.
31. Dean JB, Hayashi SS, Albert CM, King AA, Karzon R dan Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. *J Pediatr Hematol Oncol* 2008; 30:130-134
32. Smits C, Swen JS, Goverts T, Moll AC, Imhof SM, dan Meeteren AY. Asessment of hearing in very young children retinoblastoma carboplatin for retinoblastoma. *Eur. J. Cancer* 2006; 42;492-500
33. Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS dkk. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new international society of pediatric oncology Boston ototoxicity scale. *J Clin Oncol.* 2012; 30:2408-17
34. McHaney VA, Thibadoux MA, Hayes FA dan Green AA. Hearing loss in children receiving cisplatin chemotherapy. *J Pediatr* 1983; 102:314-7
35. Kennedy IC, Fitzharris BM, Colls BM dan Atkinson CH. Carboplatin is ototoxic. *Cancer Chemother Pharmacol* 1990; 26:232-4
36. Liberman PH, Schultz C, Gomez MV, Antonelli CBG, Chojniak MM dan Novaes PE. Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation. *Clin Transl Oncol.* 2011; 13:348-52
37. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, dan Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. *Pediatr Blood Cancer.* 2012; 59:144-8
38. Stohr W, Langer T, Kremes A, Bielack S, Dinnesen AL, Fres E dan Beck JD. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. *Cancer Invest.* 2005; 23:201-7
39. Kushner BH, Budnick A, Kramer K, Modak S dan Cheung NV. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. *Cancer* 2006; 107:417-22
40. Rybak LP. Ototoxicity and antineoplastic drugs. *Otolaryngol Head Neck Surg.* 1997; 7:239-43
41. Hofstetter P, Ding P, Powers N dan Salvi RJ. Quantitative relationship of carboplatin dose to magnitude of inner and outer hair cell loss and the reduction in distortion product otoacoustic emission amplitude in chinchillas. *Hearing research.* 1997;112:199-215

42. Stavoulaki P, Apostopous N, Segas J, Tsanikos M dan Adamopoulos G. Evoked otoacoustic emission – an approach for monitoring cisplatin induced ototoxicity in children. *Int. J. Pediatr. Otorhinolaryngol.* 2001; 59: 47-57
43. American Academy of Audiology. Ototoxicity monitoring. Diunduh dari <http://www.audiology.org>. Diakses 25 Juli 2011
44. Skinner R. Best practice in assessing ototoxicity in children with cancer. *Eur J Cancer.* 2004;40:2352-
45. Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Grenner J, Magnusson M dan Moell C. Long term hearing degeneration after platinum-based chemotherapy in childhood. *Int J Audiol.* 2010; 49:765-71
46. Brummet RE dan Jackson RT. Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearing. *Pharmacol Ther.* 1984; 26(2):209-19
47. Gurney JG, Tersak JM, Ness KK dkk. Hearing loss, quality of life and academic problems in long-term neuroblastoma survivors: a report from the children oncology group. *Pediatrics.* 2007; 120:1229-36
48. Bess FH, Jeanne DM, Parker DA. Children with minimal sensorineural hearing loss: prevalence, educational performance and functional status. *Ear & Hearing.* 1988; 19(5):339-54
49. Paksoy M, Ayduran E, Sanli dkk. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. *Med Oncol.* 2011; 28:615-21
50. Wimmer C, Mees K, Stumpf P dkk. Round window application of D-methionin, sodium thiosulfat, brain-derived neutropic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. *Otol Neurotol.* 2004; 25:33-40
51. Harned TN, Kalous O, Neuwelt A dkk. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. *Clin Cancer Res.* 2008; 14:533-40